Nivolumab for recurrent olfactory neuroblastoma
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests the drug nivolumab for people with a rare nasal tumor (olfactory neuroblastoma) that has come back or spread and cannot be treated with surgery or radiation. You must have already tried chemotherapy and it stopped working. The goal is to see if nivolumab can shrink the tumor or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of olfactory neuroblastoma (a rare cancer starting in the upper part of the nose).
- Your tumor has come back or spread and cannot be removed by surgery or treated with radiation.
- You have tried at least one chemotherapy treatment, and your disease got worse.
- You are in fairly good health (able to do daily activities without help, and expected to live at least 3 months).
- You have a tumor that can be measured on a scan (like a CT or MRI).
- Your blood counts and organ function (kidney, liver) are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new targeted drug called zanzalintinib for patients with olfactory neuroblastoma (a rare cancer in the nasal cavity) that has come back or spread. The drug blocks proteins that help tumors grow, and this trial will see if it can help patients who cannot have surgery or radiation.
This trial studies nivolumab (an immune therapy) for nasopharyngeal cancer that grew or returned after platinum chemotherapy. It aims to shrink tumors or slow cancer growth after standard treatment hasn’t worked.
This trial tests whether the immunotherapy drug nivolumab (Opdivo) can help treat nasopharyngeal cancer in both children and adults. It is for people who have just been diagnosed and have not yet received any cancer treatment.
This trial tests giving a combination of naxitamab, irinotecan, and temozolomide for a longer period to people whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if this approach is safe and effective.
This trial tests whether giving chemotherapy before surgery can help treat olfactory neuroblastoma, a rare type of nose cancer. It aims to see how safe and effective this approach is for people with early to advanced tumors that have not spread to other parts of the body.
This trial is testing different combinations of medicines for children with high-risk neuroblastoma that has come back. It has two paths: one for children whose disease has relapsed only once, and another for those whose disease has come back more than once. The goal is to find which treatments work best.
Hear when a new Recurrent/ Metastatic Olfactory Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.